DE69840928D1 - Nachweismethoden für reagenzien, die das "inhibitor-der-apoptose-protein" (iap) regulieren und dadurch auf die caspaseaktivität einwirken - Google Patents

Nachweismethoden für reagenzien, die das "inhibitor-der-apoptose-protein" (iap) regulieren und dadurch auf die caspaseaktivität einwirken

Info

Publication number
DE69840928D1
DE69840928D1 DE69840928T DE69840928T DE69840928D1 DE 69840928 D1 DE69840928 D1 DE 69840928D1 DE 69840928 T DE69840928 T DE 69840928T DE 69840928 T DE69840928 T DE 69840928T DE 69840928 D1 DE69840928 D1 DE 69840928D1
Authority
DE
Germany
Prior art keywords
iap
reagents
actuating
regulating
detection methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840928T
Other languages
English (en)
Inventor
John C Reed
Quinn Deveraux
Guy S Salvesen
Ryosuke Takahashi
Natalie Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Application granted granted Critical
Publication of DE69840928D1 publication Critical patent/DE69840928D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69840928T 1997-05-22 1998-04-10 Nachweismethoden für reagenzien, die das "inhibitor-der-apoptose-protein" (iap) regulieren und dadurch auf die caspaseaktivität einwirken Expired - Lifetime DE69840928D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86208797A 1997-05-22 1997-05-22
PCT/US1998/007357 WO1998053091A1 (en) 1997-05-22 1998-04-10 Screening assays for agents that alter inhibitor of apoptosis (iap) protein regulation of caspase activity

Publications (1)

Publication Number Publication Date
DE69840928D1 true DE69840928D1 (de) 2009-08-06

Family

ID=25337620

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840928T Expired - Lifetime DE69840928D1 (de) 1997-05-22 1998-04-10 Nachweismethoden für reagenzien, die das "inhibitor-der-apoptose-protein" (iap) regulieren und dadurch auf die caspaseaktivität einwirken

Country Status (6)

Country Link
EP (1) EP0983376B1 (de)
JP (2) JP4068666B2 (de)
AU (1) AU760765B2 (de)
CA (1) CA2289972C (de)
DE (1) DE69840928D1 (de)
WO (1) WO1998053091A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426411B1 (en) * 1997-05-30 2002-07-30 Dana-Farber Cancer Institute PGC-1, a novel brown fat pparγ coactivator
EP1151295A4 (de) * 1999-02-01 2005-03-30 Cytovia Inc Verfahren zur identifizierung therapeutisch effektiver antineoplastischer substanzen mittels kultivierter zellen mit intakten zellmembranen und damit zusammenhängende produkte
US6570069B1 (en) 2000-02-10 2003-05-27 Regents Of The University Of California Nucleic acids encoding plant inhibitors of apoptosis and transgenic cells and plants expressing them
US7172880B2 (en) 2001-01-08 2007-02-06 The Burnham Institute For Medical Research Inhibitor of apoptosis proteins and nucleic acids and methods for making and using them
US6911426B2 (en) * 2001-11-21 2005-06-28 The Burnham Institute Methods and compositions for derepression of IAP-inhibited caspase
US20070049602A1 (en) * 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766848A (en) * 1993-01-04 1998-06-16 Synaptic Pharmaceutical Corporation Methods for identifying compounds which specifically bind a human betaine/GABA transporter

Also Published As

Publication number Publication date
JP2006204308A (ja) 2006-08-10
EP0983376B1 (de) 2009-06-24
WO1998053091A1 (en) 1998-11-26
EP0983376A1 (de) 2000-03-08
EP0983376A4 (de) 2004-10-20
AU760765B2 (en) 2003-05-22
CA2289972A1 (en) 1998-11-26
JP4068666B2 (ja) 2008-03-26
JP2001510345A (ja) 2001-07-31
CA2289972C (en) 2011-06-07
AU6898898A (en) 1998-12-11

Similar Documents

Publication Publication Date Title
FR2721568B1 (fr) Zone éclairable.
DE69819399D1 (de) Rauchmelder und Steuersystem für die Anzeige
DE69822721D1 (de) Vorrichtung für klinische Analysen
DE69623204D1 (de) Modulares drahtloses Diagnose-, Test- und Informationssystem
DE69623312D1 (de) Lager und Überwachungssystem für Lager
PT915846E (pt) Fenilcetoenois 2-substituidos e 2,5-substituidos
NL1005115A1 (nl) Kogeltjesmatrixsondesamenstel.
IT1277860B1 (it) Dispositivo simmetrizzatore e procedimento per la sua progettazione.
DE69840928D1 (de) Nachweismethoden für reagenzien, die das "inhibitor-der-apoptose-protein" (iap) regulieren und dadurch auf die caspaseaktivität einwirken
FI900451A0 (fi) Kliniska tillaempningar.
DE69526203D1 (de) Biologische zielgerichtete mittel
FI951029A (fi) Mikroliuska-aaltoputkisiirtymä
TR199501562A2 (tr) Tiyenopiridon'lar.
DE69832152D1 (de) Lumineszenzmethode für das luciferin/luciferase-system und lumineszenzreagens
DE69733623D1 (de) Snoopbus für zerteite transaktionen und arbitrierungsverfahren
DE69722221D1 (de) Montagesystem für krankenhäuser
DE69832603D1 (de) An plasmamebranen lokalisierte sialidasen und dafür kodierende dna
FR2716759B1 (fr) Etage de formatage d'opérandes optimisé.
BR9509887A (pt) Sistema controlado por computador
ES1027007Y (es) Dispositivo facofragmentador de nucleo, desechable.
FR2721184B3 (fr) Console.
SE9702117D0 (sv) Blodanalyssystem
ES1037972Y (es) "recipiente para analisis clinicos".
ITRM960313A0 (it) Dispositivo di allarme anti-sonno per tele-video-spettatori e simili.
KR980002271U (ko) 운전자의 피로 경보장치

Legal Events

Date Code Title Description
8364 No opposition during term of opposition